Exploring Next Generation Technology in Pathogen Testing

May 11, 2018 | Original story from PathogenDx

Exploring Next Generation Technology in Pathogen Testing

Innovations with Ed Begley Jr. will explore recent developments taking place in DNA-based pathogen testing for cannabis, botanical, food and agriculture industry. This segment is scheduled to air 4th QTR 2018.


In this segment, Innovations will explore PathogenDx, whose disruptive, game-changing technology provides simple, effective, fast, and affordable DNA-based pathogen testing for cannabis, botanical, food and agriculture industry. Viewers will learn how PathogenDx has developed the next generation “standard” for very large-scale cannabis, botanical, food and agricultural testing.


The company is intentionally targeting the Cannabis sector as a break-in strategy to deliver the benefits of its technology to an industry that is experiencing significant pathogen contamination issues. Its end goal is make available its technology and products to Food, Agriculture and other markets.


“When it comes to ease of use, time savings, throughput, sensitivity and specificity; nothing comes close,” said Dr. Reggie Gaudino, Chief Scientific Officer, Steep Hill Labs – The Global Leader in Cannabis Testing & Analytics.


This technology provides people involved with all aspects of commerce in the cannabis, food and agricultural, and botanical markets the ability to quickly identify pathogen contamination in a fraction of the time, testing for multiple pathogens at the same time at a significant cost advantage compared to other commercially available technologies. The benefits are multifold from reducing risk of sickness and death, saving billions of dollars in economic losses, and improving shelf life of product.


“PathogenDx developed an innovative, novel approach to detect pathogens that harm humans, plants and the environment. Their DNA-based pathogen testing technology is light years ahead of other microbial testing methods,” said Michele Nehls, Senior Producer for the Innovations series. “We look forward to bringing this vital information to our viewers.”


This article has been republished from materials provided by PathogenDx. Note: material may have been edited for length and content. For further information, please contact the cited source.